Literature DB >> 80384

Progressive vaccinia: immunological aspects and transfer factor therapy.

L Timár, J Budai, G Nyerges, R Szigeti, I Hollós, I Sonkoly.   

Abstract

Progressive vaccinia is a rare and serious complication of smallpox vaccination. Depressed immune function can generally be found as an underlying disorder; thus adequate immuno-correction may be expected to be therapeutically effective. Humoral and cell-mediated immunity was repeatedly examined in one case throughout the course of the disease. Results indicated partial deficiency of cell-mediated immunity. No therapeutic effect was achieved by using human antivaccinia immunoglobulin and N-methylisatin beta-thiosemicarbazone. Transfer factor therapy was also attempted. Treatment with a non-specific transfer factor preparation was followed by a transitory clinical improvement. A specific transfer factor preparation given during the last month of life, however, had no therapeutic effect. The patient died on the 145th day after vaccination. Autopsy findings pointed to combined immune deficiency.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 80384     DOI: 10.1007/BF01641902

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  17 in total

1.  Studies smallpox and complications of smallpox vaccination.

Authors:  C H KEMPE
Journal:  Pediatrics       Date:  1960-08       Impact factor: 7.124

2.  PROGRESSIVE VACCINIA WITH NORMAL ANTIBODIES. A CASE POSSIBLY DUE TO DEFICIENT CELLULAR IMMUNITY.

Authors:  C J O'CONNELL; D T KARZON; A L BARRON; M E PLAUT; V M ALI
Journal:  Ann Intern Med       Date:  1964-02       Impact factor: 25.391

3.  Vaccinia gangrenosa treated with hyperimmune vaccinal gamma globulin.

Authors:  G J BARBERO; A GRAY; T F M SCOTT; C H KEMPE
Journal:  Pediatrics       Date:  1955-11       Impact factor: 7.124

4.  Fatal generalized vaccinia with failure of antibody production and absence of serum gamma globulin.

Authors:  S E KEIDAN; K MCCARTHY; J C HAWORTH
Journal:  Arch Dis Child       Date:  1953-04       Impact factor: 3.791

5.  [Immunological aspects of the susceptibility for mycotic infections].

Authors:  E Balogh; G Szegedi; L Karmazsin; G Szabó; M Szabolcsi
Journal:  Dermatol Monatsschr       Date:  1976-02

6.  Vaccinia Gangrenosa with normal humoral antibodies. A case possibly due to deficient cellular immunity treated with N-methylisatin beta-thiosemicarbazone (Compound 33T57, Marboran).

Authors:  O Hansson; S G Johansson; B Vahlquist
Journal:  Acta Paediatr Scand       Date:  1966-05

Review 7.  Transfer factor.

Authors:  H S Lawrence
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

8.  [Transfer factor. Properties and possible therapeutic applications (author's transl)].

Authors:  P J Grob; J F Reymond; M A Häcki; M Frey-Wettstein
Journal:  MMW Munch Med Wochenschr       Date:  1975-03-28

Review 9.  Smallpox vaccination reactions, prophylaxis, and therapy of complications.

Authors:  J A Goldstein; J M Neff; J M Lane; J P Koplan
Journal:  Pediatrics       Date:  1975-03       Impact factor: 7.124

10.  The human rosette-forming cell as a marker of a population of thymus-derived cells.

Authors:  J Wybran; M C Carr; H H Fudenberg
Journal:  J Clin Invest       Date:  1972-10       Impact factor: 14.808

View more
  1 in total

1.  Lung involvement in progressive vaccinia.

Authors:  D S Chudwin; M J Cowan; D W Wara; A C Johnson
Journal:  West J Med       Date:  1981-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.